Towards Precision Medicine in Systemic Lupus Erythematosus

References

• Lisnevskaia L, Murphy G, Isenberg DA. Systemic lupus erythematosus. Lancet. 2014;384:1878–1888. doi:10.1016/S0140-6736(14)60128-824881804
   PubMed Web of Science ®Google Scholar
• Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018;9:2279. doi:10.3389/fimmu.2018.0227930337927
   PubMed Web of Science ®Google Scholar
• Sharif K, Watad A, Coplan L, et al. The role of stress in the mosaic of autoimmunity: an overlooked association. Autoimmun Rev. 2018;17:967–983. doi:10.1016/j.autrev.2018.04.00530118900
   PubMed Web of Science ®Google Scholar
• Smatti MK, Cyprian FS, Nasrallah GK, et al. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses. 2019;11(8):762. doi:10.3390/v11080762
   PubMed Web of Science ®Google Scholar
• Barbhaiya M, Tedeschi SK, Lu B, et al. Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the nurses’ health study cohorts. Ann Rheum Dis. 2018;77:196–202. doi:10.1136/annrheumdis-2017-21167528988206
   PubMed Web of Science ®Google Scholar
• Mak A, Tay SH. Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci. 2014;15(9):16043–16056. doi:10.3390/ijms15091604325216337
   PubMed Web of Science ®Google Scholar
• Mu Q, Zhang H, Luo XM. SLE: another autoimmune disorder influenced by microbes and diet? Front Immunol. 2015;6:608. doi:10.3389/fimmu.2015.0060826648937
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the systemic lupus erythematosus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–2686. doi:10.1002/art.3447322553077
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi:10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader KH, Daikh D, et al. European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151–1159. doi:10.1136/annrheumdis-2018-21481931383717
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader KH, Brinks R, et al. Validation of new systemic lupus erythematosus classification criteria. Ann Rheum Dis. 2018;77:60–62. doi:10.1136/annrheumdis-2017-212463
   Web of Science ®Google Scholar
• Gegenava M, Beaart HJL, Monahan RC, et al. Performance of the proposed ACR-EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms. RMD Open. 2019;5:e000895. doi:10.1136/rmdopen-2019-00089531245049
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–745. doi:10.1136/annrheumdis-2019-21508930926722
   PubMed Web of Science ®Google Scholar
• Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, Isenberg DA. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res. 2016;68:981–987. doi:10.1002/acr.v68.7
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptosis and clearance of apoptotic cells. Annu Rev Immunol. 2018;36:489–517. doi:10.1146/annurev-immunol-042617-05301029400998
   PubMed Web of Science ®Google Scholar
• Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opinion Rheum. 2015;5:448–453. doi:10.1097/BOR.0000000000000197
   Web of Science ®Google Scholar
• Urbonaviciute V, Luo H, Sjöwall C, Bengtsson A, Holmdahl R. Low production of reactive oxygen species drives systemic lupus erythematosus. Trends Mol Med. 2019;25:826–835. doi:10.1016/j.molmed.2019.06.00131303528
   PubMed Web of Science ®Google Scholar
• Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011;7:691–699. doi:10.1038/nrrheum.2011.13221947176
   PubMed Web of Science ®Google Scholar
• Frangou E, Vassilopoulos D, Boletis J, Boumpas DT, Boletis J. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment. Autoimmun Rev. 2019;18:751–760. doi:10.1016/j.autrev.2019.06.01131181324
   PubMed Web of Science ®Google Scholar
• Delgado-Rizo V, Martínez-Guzmán MA, Iñiguez-Gutierrez L, et al. Neutrophil extracellular traps and its implications in inflammation: an overview. Front Immunol. 2017;8(1–20):81. doi:10.3389/fimmu.2017.0008128220120
   PubMed Web of Science ®Google Scholar
• Herrada AA, Escobedo N, Iruretagoyena M, et al. Innate immune cells’ contribution to systemic lupus erythematosus. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.00772
   Web of Science ®Google Scholar
• Shin JI, Lee KH, Joo YH, et al. Inflammasomes and autoimmune and rheumatic diseases: A comprehensive review. J Autoimmun. 2019;103:102299. doi:10.1016/j.jaut.2019.06.01031326231
   PubMed Web of Science ®Google Scholar
• Ma C, Xia Y, Yang Q, et al. The contribution of macrophages to systemic lupus erythematosus. Clin Immunol. 2019;207:1–9. doi:10.1016/j.clim.2019.06.00931255802
   PubMed Web of Science ®Google Scholar
• Thorlacius GE, Wahren-Herlenius M, Rönnblom L. An update on the role of type I interferons in systemic lupus erythematosus and Sjögren’s syndrome. Curr Opin Rheumatol. 2018;30:471–478. doi:10.1097/BOR.000000000000052429889694
   PubMed Web of Science ®Google Scholar
• Celhar T, Fairhurst A. Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. Frontiers Pharmacol. 2014;5(265):1–8. doi:10.3389/fphar.2014.00265
   Web of Science ®Google Scholar
• Worbs T, Hammerschmidt SI, Förster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17:30–48. doi:10.1038/nri.2016.11627890914
   PubMed Web of Science ®Google Scholar
• Klarquist J, Zhou Z, Shen N, Janssen EM. Dendritic cells in systemic lupus erythematosus: from pathogenic players to therapeutic tools. Mediators Inflamm. 2016;2016:5045248. doi:10.1155/2016/5045248
   Web of Science ®Google Scholar
• Sandhu V, Quan M. SLE and serum complement: causative, concomitant or coincidental. Open Rheumatol. 2017;11:113–122. doi:10.2174/1874312901711010113
   PubMedGoogle Scholar
• Zhou H, Li B, Li J, et al. Dysregulated T-cell activation and aberrant cytokine expression profile in systemic lupus erythematosus. Mediators of Inflamm. 2019;2019. doi:10.1155/2019/8450947
   Web of Science ®Google Scholar
• SL P. Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev. 2009;8:179–183. doi:10.1016/j.autrev.2008.07.04018721908
   PubMed Web of Science ®Google Scholar
• Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun. 2018;87:1–15. doi:10.1016/j.jaut.2017.12.00729275836
   PubMed Web of Science ®Google Scholar
• Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45:344–355. doi:10.1002/eji.20134428025378177
   PubMed Web of Science ®Google Scholar
• Blanco P, Ueno H, Schmitt N. T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis. Eur J Immunol. 2016;46:281–290. doi:10.1002/eji.20154576026614103
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Lewis M, Pitzalis C. Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nat Rev Rheumatol. 2017;13:141–154. doi:10.1038/nrrheum.2016.21728202919
   PubMed Web of Science ®Google Scholar
• Costa S, Bevilacqua D, Cassatella MA. Recent advances on the crosstalk between neutrophils and B or T lymphocytes. Immunology. 2019;156:23–32. doi:10.1111/imm.1300530259972
   PubMed Web of Science ®Google Scholar
• Karrar S, Cunningham-Graham D. Abnormal B-cell development in systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:496–502. doi:10.1002/art.4039629207444
   PubMed Web of Science ®Google Scholar
• Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus: past, imperfect, future tense? Nat Rev Rheum. 2019;15:403–412. doi:10.1038/s41584-019-0235-5
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533. doi:10.1056/NEJMoa02193314561795
   PubMed Web of Science ®Google Scholar
• Flower C, Hennis A, Hambleton IR, Nicholson G. Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes. Lupus. 2006;15(10):689–694. doi:10.1177/096120330607241517120598
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Fragoulis GE, Somarakis G, Drosos A, Tzioufas AG, Moutsopoulos HM. Clinical and laboratory predictors of distinct histopathological features of lupus nephritis. Medicine. 2015;94:1–8. doi:10.1097/MD.0000000000000829
   Web of Science ®Google Scholar
• Yu F, Haas M, Glassock R, et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483–495. doi:10.1038/nrneph.2017.8528669995
   PubMed Web of Science ®Google Scholar
• Londoño Jiminez A, Mowrey WB, Putternam C, Buyon J, Goilav B, Broder A. Brief report: tubulointerstitial damage in lupus nephritis: A comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheumatol. 2018;70:1801–1806. doi:10.1002/art.4057529851285
   PubMed Web of Science ®Google Scholar
• Arazi A, Rao DA, Berthier CC etal,. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20:902–914. doi:10.1038/s41590-019-0398-x31209404
   PubMed Web of Science ®Google Scholar
• Yung S, Chan TM. Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis. Clin Immunol. 2017;185:40–50. doi:10.1016/j.clim.2016.09.00227612436
   PubMed Web of Science ®Google Scholar
• Nalewajska M, Gurazda K, Styczyńska-Kowalska E, et al. The role of MicroRNAs in selected forms of glomerulonephritis. Int J Mol Sci. 2019;20:1–9. doi:10.3390/ijms20205050
   Web of Science ®Google Scholar
• Sakhi H, Moktefi A, Bouachi K, et al. Podocyte injury in lupus nephritis. J Clin Med. 2019;8:1340. doi:10.3390/jcm8091340
   Web of Science ®Google Scholar
• Mejía-Vilet JM, Córdova-Sánchez BM, Uribe-Uribe NO, Correa-Rotter R, Morales-Buenrostro LE. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus. 2017;26:1042–1050. doi:10.1177/096120331769241928178879
   PubMed Web of Science ®Google Scholar
• Jafri K, Patterson SL, Lanata C. Central nervous system manifestations of systemic lupus erythematosus. Rheumatic Dis Clin N Am. 2017;43:531–548. doi:10.1016/j.rdc.2017.06.003
   Web of Science ®Google Scholar
• Hanly J, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;10:1726–1732. doi:10.1136/ard.2010.148502
   Web of Science ®Google Scholar
• McGlasson S, Wiseman S, Wardlaw J, Dhaun N, Hunt DPJ. Neurological disease in lupus: toward a personalized medicine approach. Front Immunol. 2018;9(1146):1–12. doi:10.3389/fimmu.2018.0114629403488
   PubMed Web of Science ®Google Scholar
• Tchessalova D, Posillico CK, Tronson NC. Neuroimmune activation drives multiple brain states. Front Syst Neurosci. 2018;12:39. doi:10.3389/fnsys.2018.00039
   Web of Science ®Google Scholar
• Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol. 2019;15:137–152. doi:10.1038/s41584-018-0156-830659245
   PubMed Web of Science ®Google Scholar
• Stock AD, Ben-Zui A, Putterman C. Pathogenesis of neuropsychiatric lupus In: Wallace DJ, Hahn BH, editors. Dubois Lupus Erythematosus and Related Symptoms. 9th ed. Elsevier; 317.23. doi:10.1186/s13075-018-1604-1
   Google Scholar
• Julià A, López-Longo FJ, Pérez Venegas JJ, et al. Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. Arthritis Ther Res. 2018;1(100):1–10. doi:10.1186/s13075-018-1604-1
   Web of Science ®Google Scholar
• Amlöf JC, Alexsson A, Imgenberg-Kreuz J, et al. Novel risk genes for systemic lupus erythematosus predicted by random forest classification. Sci Rep. 2017;1(6236):1–11. doi:10.1038/s41598-017-06516-1
   Web of Science ®Google Scholar
• Catalina MD, Owen KA, Labonte AC, Grammer AC, Lipsky PE, Labonte AC. The pathogenesis of systemic lupus erythematosus: harnessing big data to understand the molecular basis of lupus. J Autoimmun. 2019;2:102359. doi:10.1016/j.jaut.2019.102359
   Web of Science ®Google Scholar
• Surace AEA, Hedrich CM. The role of epigenetics in autoimmune/inflammatory disease. Front Immunol. 2019. doi:10.3389/fimmu.2019:01525
   Google Scholar
• Imgenberg-Kreuz J, Carlsson Almlöf J, Leonard D, et al. DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018;77(5):736–743. doi:10.1136/annrheumdis-2017-21237929437559
   PubMed Web of Science ®Google Scholar
• Hedrich CM. Epigenetics in SLE. Curr Rheumatol Rep. 2017;19(58):1–13. doi:10.1007/s11926-017-0685-128116577
   PubMed Web of Science ®Google Scholar
• Wang Z, Yin H, Lau CS, Lu Q. Histone posttranslational modifications of CD4+ T cell in autoimmune diseases. Int J Mol Sci. 2016;17(1547):1–16. doi:10.3390/ijms18010001
   Web of Science ®Google Scholar
• Wu Z, Mei X, Ying Z, Sun Y, Song J, Shi W. Ultraviolet B inhibition of DNMT1 activity via AhR activation dependent SIRT1 suppression in CD4+ T cells from systemic lupus erythematosus patients. J Dermatol Sci. 2017;86:230–237. doi:10.1016/j.jdermsci.2017.03.00628336124
   PubMed Web of Science ®Google Scholar
• Mak A. The impact of vitamin D on the immunopathophysiology, disease activity, and extra-musculoskeletal manifestations of systemic lupus erythematosus. Int J Mol Sci. 2018;19:2355; 1–14. doi:10.3390/ijms19082355
   Web of Science ®Google Scholar
• Draborg A, Izarzugaza JM, Houen G. How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases? Curr Opin Rheumatol. 2016;28:398–404. doi:10.1097/BOR.000000000000028926986247
   PubMed Web of Science ®Google Scholar
• Myers DR, Wheeler B, Roose JP. mTOR and other effector kinase signals that impact T cell function and activity. Immunol Rev. 2019;291:134–153. doi:10.1111/imr.v291.131402496
   PubMed Web of Science ®Google Scholar
• Zhang J1, Yuan B, Zhang F, et al. Cyclophosphamide perturbs cytosine methylation in Jurkat-T cells through LSD1-mediated stabilization of DNMT1 protein. Chem Res Toxicol. 2011;24:2040–2043. doi:10.1021/tx200384922007908
   PubMed Web of Science ®Google Scholar
• Silverman GJ. The microbiome in SLE pathogenesis. Nat Rev Rheumatol. 2019;15(2):72–74.30607012
   PubMed Web of Science ®Google Scholar
• Kim JW, Kwok SK, Choe JY, et al. Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus. Int J Mol Sci. 2019;20(19). doi:10.3390/ijms20194871.
   Web of Science ®Google Scholar
• Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018;359(6380):1156–1161. doi:10.1126/science.aar720129590047
   PubMed Web of Science ®Google Scholar
• Mu Q, Zhang H, Liao X, et al. Control of lupus nephritis by changes of gut microbiota. Microbiome. 2017;5(1):73. doi:10.1186/s40168-017-0300-828697806
   PubMed Web of Science ®Google Scholar
• Greiling TM, Dehner C, Chen X, et al. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Sci Transl Med. 2018;10(434). doi:10.1126/scitranslmed.aan2306.
   PubMed Web of Science ®Google Scholar
• Cuervo A, Hevia A, López P, et al. Association of polyphenols from oranges and apples with specific intestinal microorganisms in systemic lupus erythematosus patients. Nutrients. 2015;7(2):1301–1317. doi:10.3390/nu702130125690419
   PubMed Web of Science ®Google Scholar
• Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57:e1–45. doi:10.1093/rheumatology/kex28629029350
   PubMed Web of Science ®Google Scholar
• Da Costa R, Aguirre-Alastuey E, Isenberg DA, Saracino A. Assessment of response to B-cell depletion using Rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154(12):1432–1440. doi:10.1001/jamadermatol.2018.37930383114
   PubMed Web of Science ®Google Scholar
• Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S37–46. doi:10.1002/acr.2057222588757
   PubMed Web of Science ®Google Scholar
• Yee CS, Isenberg DA, Prabu A, et al. BILAG 2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis. 2008;67(21):873–876. doi:10.1136/ard.2007.07084717519277
   PubMed Web of Science ®Google Scholar
• Freitas S, Mozo Ruiz M, Costa Carneiro A, Isenberg DA. Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?Clin Exp Rheumatol. 2019;58(Supplement_3):kez107–055 In Press.
   Google Scholar
• Plant D, Maciejewski M, Smith S, Nair N. Maximising therapeutic utility in rheumatoid arthritis consortium, the RAMS study group, Hyrich K1, Ziemek D2, Barton A1, Verstappen S1 Profiling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:678–684. doi:10.1002/art.4081030615300
   PubMed Web of Science ®Google Scholar
• Merrell M, Shulman LE. Determination of prognosis in chronic disease illustrated by systemic lupus erythematosus. J Chronic Dis. 1955;1:12–32. doi:10.1016/0021-9681(55)90018-713233308
   PubMedGoogle Scholar
• Mak A, Cheung MW-L, Chiew KJ, et al. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum. 2012;41:830–839. doi:10.1016/j.semarthrit.2011.11.00222257558
   PubMed Web of Science ®Google Scholar
• Dooley MA, Hogan S, Falk R. Cyclophosphamide therapy for lupus nephritis: poor survival in black Americans. glomerular disease collaborative network. Kidn Int. 1997;51:1188–1195. doi:10.1038/ki.1997.162
   PubMed Web of Science ®Google Scholar
• Ciurtin C, Isenberg DA, Eds. Biologics in Rheumatology. New York: Nova Biomedical; 2016.
   Google Scholar
• Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictions of response. Ann Rheum Dis. 2012;71:1343–1349. doi:10.1136/annrheumdis-2011-20093722337213
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment and management of lupus nephritis. Arthritis Care Res. 2012;64:797–808. doi:10.1002/acr.21664
   PubMed Web of Science ®Google Scholar
• Bertsios G, Tektonidou M, Amura Z, et al. Joint European League Against Rheumatism and European Renal Association – European Dialysis and Transplant Association [EULAR/ERA-EDTA] recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:177–182.
   Web of Science ®Google Scholar
• Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535–1543. doi:10.2147/DDDT.S170969
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of Atacicept in patients with systemic lupus erythematosus. Arthritis Rheum. 2018;70:266–276. doi:10.1002/art.40360
   PubMed Web of Science ®Google Scholar
• Laccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1–8. doi:10.1016/j.jaut.2017.09.00428935492
   PubMed Web of Science ®Google Scholar
• Piantoni S, Andreoli L, Lowin T. Baseline serum levels of baff or april are independent predictors of sledai response after 12 months of treatment with belimumab in patients with refractory systemic lupus erythematosus. doi:10.1136/lupus-2018-abstract.43
   Google Scholar
• Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K, Gomez A. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2019;58(12):2170–2176. doi:10.1093/rheumatology/kez19131157891
   PubMed Web of Science ®Google Scholar
• Alase A, Wigston Z, Burska A. Prediction of response to rituximab in SLE using a validated two-score system for interferon status. doi:10.1136/lupus-2019-lsm.71
   Google Scholar
• Suttichet TB, Kittanamongkolchai W, Phromjeen C. Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study. Lupus Sci Med. 2019 eCollection 2019. doi:10.1136/lupus-2018-000298
   Web of Science ®Google Scholar
• Mendoza-Pinto C, Pirone C, van der Windt DA. Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? Syst Rev Semin Arthritis Rheum. 2017;47:65–76.
   Web of Science ®Google Scholar